DuPont spent US$1.2M in Q3 on lobbing, flat from same quarter last year; lobbying interests included chemical regulations, childhood obesity

Alison Gallant

Alison Gallant

Dec 13, 2011 – Associated Press

December 13, 2011 () – DuPont spent $1.2M in the 3Q to lobby on topics from chemical regulation to childhood obesity

Du Pont Co. spent $1.21 million in the third quarter to lobby the government on a range of issues from chemical regulation to childhood obesity, according to a disclosure report.

That's the same amount the Wilmington, Del., chemical manufacturer spent a year earlier and in the second quarter, according to quarterly disclosure reports it has filed with the House clerk's office.

From July to September, E.I. du Pont de Nemours & Co. discussed several issues including competition in agriculture, nutrition laws, chemicals used on crops, climate change, taxes and trade. Other topics included child obesity, appropriations for some federal agencies, international chemical regulations and energy efficiency. The company also discussed security for chemical facilities, trade and rail competition.

In addition to both houses of Congress, du Pont lobbied the Environmental Protection Agency, the Food and Drug Administration, the Executive Office of the President and other federal agencies, according to its Oct. 20 report.

© 2021 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Share:

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025 795

+1 (310) 558 0008
+1 (310) 558 0080 (FAX)

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.